Apr 29, 2020
Bayer and OrigiMed reached a partnership to develop a next generation sequencing (NGS) based companion diagnostic-in vitro diagnostic (CDx-IVD) product in China for Larotrectinib, for NTRK gene fusion detection
Jan 09, 2020
Aliyanna Overcomes the Odds, Celebrates Her Second Birthday with Her Care Team
Nov 21, 2019
Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer
Sep 28, 2019
Bayer Announces Updated Analysis for Vitrakvi® (larotrectinib) Demonstrating High Response Rate and Duration of Response of Nearly Three Years in Adults and Children with TRK Fusion Cancer
Aug 15, 2019
FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
Jul 30, 2019
Health Canada approves VITRAKVI® (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion
Jun 03, 2019
New data on Vitrakvi® (larotrectinib) in TRK fusion cancer patients with brain metastases or primary central nervous system (CNS) tumors
May 29, 2019
Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference
May 15, 2019
Bayer presents new analyses for Vitrakvi® (larotrectinib) in adult and pediatric patients with TRK fusion cancer with solid tumors, and new data in primary central nervous system tumors and brain metastases
Apr 30, 2019
Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019
Mar 05, 2019
Array BioPharma to Present at the 39th Annual Cowen Health Care Conference
Feb 21, 2019
Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
Feb 15, 2019
Bayer to obtain full rights to global development and commercialization of oncology compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)
Feb 15, 2019
Lilly Completes Acquisition of Loxo Oncology
Jan 29, 2019
Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019
Jan 07, 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Dec 20, 2018
Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 26, 2018
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
Nov 20, 2018
Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
Nov 06, 2018
Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference